Lung Cancer

From “Star Trek” actors supporting the Pancreatic Cancer Action Network to Michelle Obama meeting with a sarcoma survivor and an update on Jane Fonda’s cancer, here’s what’s happening in the cancer space this week.

Does lung cancer screening continue after a person is finished with treatment and moves in to the survivorship stage?

Identifying genetic mutations in lung cancer has allowed researchers to develop treatments that target specific biomarkers over the past 20 years, but more research is needed to further the space.

Patients should describe their symptoms in detail and seek early care for suspected lung cancer, especially since the disease may resemble pneumonia and bronchitis on imaging tests.

Light exercises, which can be done at home, may be beneficial for patients with lung cancer.

Imjudo, Imfinzi and chemotherapy improved overall and progression-free survival in certain patients with non-small cell lung cancer.

New treatments may stall lung cancer progression in patients with EGFR exon 20 insertion mutations.

The Food and Drug Administration approved Libtayo plus chemotherapy for certain patients with non-small cell lung cancer.

Tumors can spread from one lung to the other and beyond. How are possible cancer metastases diagnosed in early stages?

A novel drug, MRT-2359, will be studied in a phase 1/2 trial for patients with MYC-driven cancers.

Talking about the end of life can be difficult, but these conversations are crucial for patients with incurable cancer to have with their clinicians, experts say.

A clinical trial recently kicked off to study the effects of combining the novel drug BBP-398 plus Lumakras in patients with lung cancer that harbors a KRAS G12 mutation.

Watch Dr. Hossein Borghaei, Dr. David Gerber, Dr. Aaron S. Mansfield and Dana M. Haagen answer questions on the management of advanced/metastatic disease during the CURE Educated Patient Lung Cancer Summit.

Watch Dana Haagen, from Fox Chase Cancer Center, discuss clinical trials and how patients can join them, during the CURE® Educated Patient® Lung Cancer Summit.

Watch Dr. Aaron S. Mansfield, from Mayo Clinic, discuss the management of mesothelioma during the CURE Educated Patient Lung Cancer Summit.

Watch Dr. David Gerber, from UT Southwestern Medical Center, discuss antibody drug conjugates during the CURE Educated Patient Lung Cancer Summit.

Watch Dr. Hossein Borghaei, Dr. Jared Weiss and Dr. Anne Chiang answer questions about early disease management during the CURE Educated Patient Lung Cancer Summit.

I sent all my cancer scans to my pediatrician, who combined the power of science with the power of belief and helped me through the difficult time.

From Kevin Durant’s sneaker that is raising money for cancer to Khloe Kardashian’s urging people to check for moles and melanoma, here’s what’s happening in the cancer space this week.

Watch Dr. Anne Chiang, from Yale School of Medicine, discuss molecular testing and adjuvant targeted therapies during the CURE Educated Patient Lung Cancer Summit.

Watch Dr. Jared Weiss, from UNC School of Medicine, discuss neoadjuvant versus adjuvant therapy during the CURE Educated Patient Lung Cancer Summit.

I went from being an avid runner to running from information about my lung cancer. But now I embrace my diagnosis and am an active participant in my care.

An oncology nurse and cancer survivor inspired another person with lung cancer to “continue the fight to live.”

Dr. Estelamari Rodriguez serves patients with lung cancer in more than just a clinical capacity, her Lung Cancer Hero® nominator wrote.

The use of a multi-agent chemotherapy regimen resulted in improved outcomes in a group of children with pleuropulmonary blastoma, a rare form of lung cancer, when compared with other regimens.

Treatment with an investigational drug elicited a median progression-free survival (time from treatment until disease progression or death) of 8.9 months among patients with a form of unresectable or metastatic squamous non-small cell lung cancer, according to trial findings.

Dr. Pierre de Delva works tirelessly to bring better outcomes to patients with lung cancer who live in Mississippi — a state that traditionally has poor lung cancer outcomes.

After being diagnosed with late-stage cancer, I learned many lessons, including the fact that I had to be my own best advocate.

The FDA’s approval of Vegzelma was based on data that demonstrated the biosimilar elicited comparable safety and efficacy to Avastin in several studies.